65% PROFIT ON ELI LILLY — 20% REDUCTION IN HEART ATTACKS AND STROKES WITH WEIGHT LOSS DRUG — RAISING THE TARGET
By Nigam Arora & Dr. Natasha Arora
Signal Limited is a Signal(s) with a great record in similar situations but does not meet all of the stringent criteria for a Signal. Typically Signal Limited has higher risk-reward compared to a Signal over the short term.
Good News
The results are out from the large scale study known as SELECT. The study was conducted by Danish company Novo Nordisk (NVO). The study compared in a double blind trial once weekly semaglutide 2.4mg with placebo over a period of five years. The study showed a reduction in major adverse cardiovascular events by about 20% with semaglutide.… Please click here or the title below to read more.
August 9, 2023